This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-MHC class II IgG to GM-CSF. It was expressed in CHO and purified with affinity chromatography. This antibody-cytokine fusion protein retains GM-CSF bioactivity, evaluated by its ability to induce the formation of hematopoietic progenitor colonies from bone marrow mononuclear cells, and also retains the ability to bind the antigens on the surface of cancer cells that express MHC class II. It also demonstrated ADCC in vitro, using human mononuclear cells as effectors. This immunocytokine was designed for treating B-cell NHL and chronic lymphocytic leukemia.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-661 | Recombinant Anti-MHC class II Antibody | ELISA, WB, FuncS | IgG |
MHH-661 | Recombinant Human Anti-MHC class II Antibody | WB, IF, FuncS | IgG |
FN-112CQ | Recombinant Mouse Anti-MHC class II Antibody (Y-3) | FC, FuncS | Mouse IgG2b, κ |
VS3-WK223 | Rabbit Anti-MHC Class II Recombinant Antibody (clone JA10-94) | WB, IP, ICC, IF, IHC | Rabbit IgG |
There are currently no Customer reviews or questions for ACFP-SH024. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.